Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03461861 · ClinicalTrials.gov registry record · Phase 2
Network-Level Mechanisms for Preclinical Alzheimer's Disease Development
A Phase 2 study of Apoe 4, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT03461861 is a Phase 2 study of Apoe 4 that has completed, run by Medical College of Wisconsin. The registered enrollment target is 26 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03461861, a Phase 2 study of Apoe 4, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus in normal, healthy adults. The investigators will compare the functional connectivity results after taking AGB101 or placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AGB101 220 mg
Study Locations (1)
Wisconsin
- Froedtert & The Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-04-11 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03461861
The ClinicalTrials.gov registry entry for NCT03461861 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Apoe 4 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03461861 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03461861 about?
NCT03461861 is a clinical study titled "Network-Level Mechanisms for Preclinical Alzheimer's Disease Development". The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus in normal, healthy adults. The investigators will compare the functional connectivity results after taking AGB101 or p...
What is the current status of trial NCT03461861?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2019-04-11. Estimated completion is 2021-03-31.
What conditions does trial NCT03461861 study?
This clinical trial studies the following conditions: Apoe 4.
What interventions are being tested in trial NCT03461861?
The interventions under investigation include: Placebo (OTHER), AGB101 220 mg (DRUG).
Who is sponsoring clinical trial NCT03461861?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03461861 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.